Shiraj Sen

1.7k total citations
57 papers, 1.1k citations indexed

About

Shiraj Sen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shiraj Sen has authored 57 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 18 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shiraj Sen's work include Cardiovascular Function and Risk Factors (7 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Genomics and Diagnostics (6 papers). Shiraj Sen is often cited by papers focused on Cardiovascular Function and Risk Factors (7 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Genomics and Diagnostics (6 papers). Shiraj Sen collaborates with scholars based in United States, United Kingdom and Japan. Shiraj Sen's co-authors include Heinrich Taegtmeyer, Deborah Vela, David S. Hong, Bijoy Kundu, Roberto Carmagnani Pestana, Vivek Subbiah, Brian P. Hobbs, Deborah M. Muoio, Monte S. Willis and Steven M. Watkins and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shiraj Sen

53 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shiraj Sen United States	16	544	385	198	195	165	57	1.1k
Shuguang Zhu China	17	493 0.9×	153 0.4×	210 1.1×	160 0.8×	112 0.7×	48	1.1k
Su Wang China	14	441 0.8×	385 1.0×	141 0.7×	168 0.9×	65 0.4×	51	990
Fangping Xu China	16	312 0.6×	119 0.3×	235 1.2×	96 0.5×	129 0.8×	52	847
Brett E. Fenster United States	19	431 0.8×	445 1.2×	128 0.6×	394 2.0×	320 1.9×	36	1.5k
Chu Kataoka Japan	14	390 0.7×	334 0.9×	262 1.3×	151 0.8×	219 1.3×	17	1.3k
Xuyang Peng China	13	350 0.6×	441 1.1×	217 1.1×	85 0.4×	61 0.4×	27	838
Elena V. Efimova United States	20	576 1.1×	146 0.4×	378 1.9×	101 0.5×	110 0.7×	53	1.1k
Nadeem Wajih United States	18	378 0.7×	128 0.3×	105 0.5×	92 0.5×	184 1.1×	31	1.2k
Swaminathan Murugappan United States	15	336 0.6×	351 0.9×	382 1.9×	204 1.0×	38 0.2×	27	1.3k
Malik Bisserier United States	19	657 1.2×	310 0.8×	98 0.5×	499 2.6×	101 0.6×	48	1.2k

Countries citing papers authored by Shiraj Sen

Since Specialization

Citations

This map shows the geographic impact of Shiraj Sen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiraj Sen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiraj Sen more than expected).

Fields of papers citing papers by Shiraj Sen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiraj Sen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiraj Sen. The network helps show where Shiraj Sen may publish in the future.

Co-authorship network of co-authors of Shiraj Sen

This figure shows the co-authorship network connecting the top 25 collaborators of Shiraj Sen. A scholar is included among the top collaborators of Shiraj Sen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiraj Sen. Shiraj Sen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Jianhui, Arkene Levy, Zhen Cai, et al.. (2025). Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. Molecular Cancer Therapeutics. 24(8). 1171–1185. 1 indexed citations

Braicu, Elena Ioana, Shiraj Sen, Valentina Boni, et al.. (2025). LBA43 NAPISTAR 1-01: A phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC). Annals of Oncology. 36. S1586–S1587.

Gubens, Matthew A., Shiraj Sen, Mohamad A. Salkeni, et al.. (2024). P2.10A.02 Phase 1/1b Trial of MBRC-101, An Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid Tumors. Journal of Thoracic Oncology. 19(10). S243–S244. 1 indexed citations

Spira, Alexander I., Michael S. Gordon, Jason T. Henry, et al.. (2023). 756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors. SHILAP Revista de lepidopterología. A852–A852. 1 indexed citations

Sen, Shiraj, Alexander I. Spira, David Sommerhalder, et al.. (2023). 1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. Annals of Oncology. 34. S649–S650. 2 indexed citations

Jankú, Filip, Milind Javle, Shiraj Sen, et al.. (2023). A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors. Cancer. 129(10). 1537–1546. 1 indexed citations

Pestana, Roberto Carmagnani, Jason Roszik, Roman Groisberg, et al.. (2021). Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Current Problems in Cancer. 45(5). 100794–100794. 5 indexed citations

Chung, Christine, et al.. (2020). Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Eligible for Early-Phase Clinical Trials. PubMed. 34(3410). 407–412. 5 indexed citations

Sen, Shiraj, Ryuma Tanaka, Soumen Khatua, et al.. (2020). Dual inhibition of BRAF and mTOR in BRAF^V600E-mutant pediatric, adolescent, and young adult brain tumors. Molecular Case Studies. 6(4). a005041–a005041. 6 indexed citations

10.

Pestana, Roberto Carmagnani, Shiraj Sen, Brian P. Hobbs, & David S. Hong. (2020). Histology-agnostic drug development — considering issues beyond the tissue. Nature Reviews Clinical Oncology. 17(9). 555–568. 52 indexed citations

11.

Sen, Shiraj & Rachna T. Shroff. (2019). Emerging Targeted and Immunotherapies in Cholangiocarcinoma. 15(2). 71–71. 2 indexed citations

12.

Sen, Shiraj, Kenneth R. Hess, David S. Hong, et al.. (2018). Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer. 118(6). 763–769. 28 indexed citations

13.

Gupta, Arjun, Shiraj Sen, Eileen M. Marley, Weina Chen, & Harris Naina. (2016). Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience. Clinical Lymphoma Myeloma & Leukemia. 16. S175–S180. 12 indexed citations

14.

Gupta, Arjun, Jan Petrášek, Shiraj Sen, Purva Gopal, & Harris Naina. (2015). Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment. Clinical Lymphoma Myeloma & Leukemia. 16(2). e11–e14. 8 indexed citations

15.

Sen, Shiraj, Arjun Gupta, Paul M. Friedman, & Harris Naina. (2015). Bilateral Facial Nerve Palsy in Acute B Cell Lymphoblastic Leukemia: A Case Report and Review of the Literature. Indian Journal of Hematology and Blood Transfusion. 32(S1). 15–19. 5 indexed citations

16.

Sen, Shiraj, et al.. (2012). Targeted Metabolic Imaging to Improve the Management of Heart Disease. JACC. Cardiovascular imaging. 5(2). 214–226. 23 indexed citations

17.

Sen, Shiraj, et al.. (2008). Reverse phase high performance liquid chromatographic method for the analysis of letrozole in pharmaceutical dosage forms. Indian Journal of Pharmaceutical Sciences. 70(3). 401–401. 15 indexed citations

18.

Kaya, Handan, et al.. (2008). Immunoexpression of HER family, neuregulin, MAPK and AKT in invasive ductal carcinomas of the breast.. PubMed. 29(4). 350–6. 4 indexed citations

19.

Sharma, Saumya, Heinrich Taegtmeyer, Julia Adrogue, et al.. (2004). 404-4 Dynamic changes of gene expression in hypoxia-induced right ventricular hypertrophy. Journal of the American College of Cardiology. 43(5). A532–A532. 6 indexed citations

20.

Sharma, Saumya, Heinrich Taegtmeyer, Julia Adrogue, et al.. (2004). Dynamic changes of gene expression in hypoxia-induced right ventricular hypertrophy. American Journal of Physiology-Heart and Circulatory Physiology. 286(3). H1185–H1192. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact